TNF and inflammatory bowel disease: A recent meta-analysis reported limited treatment efficacy of biologics targeting TNF, α4β7-Integrin, and JAK signaling—such as infliximab, adalimumab, vedolizumab, and tofacitinib—in PSC-IBD, underscoring the inherent difference from sole IBD and the incomplete understanding of the PSC-IBD disease entity.